Chronic β-agonist administration affects cardiac function of adult but not old rats, independent of β-adrenoceptor density

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 1 58-1, 2005, Pages

  Gregorevic, Paul ^a   Ryall, James G ^a   Plant, David R ^a   Sillence, Martin N ^b   Lynch, Gordon S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Adrenergic agonists; Aging; Hypertrophy; Receptors; Ventricular function

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FENOTEROL;

AGE; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORRELATION ANALYSIS; DRUG EFFECT; HEART FUNCTION; HEART HYPERTROPHY; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILE FORCE; HEART OUTPUT; HEART VOLUME; HYPERTROPHY; IN VITRO STUDY; ISOLATED HEART; MALE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; SKELETAL MUSCLE;

ADRENERGIC BETA-AGONISTS; AGING; ANIMALS; BODY WEIGHT; CARDIAC OUTPUT; CARDIOMEGALY; CORONARY CIRCULATION; DRUG ADMINISTRATION SCHEDULE; FENOTEROL; HEART; HEART RATE; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; ORGAN SIZE; RATS; RATS, INBRED F344; RECEPTORS, ADRENERGIC, BETA;

EID: 21644438991     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01254.2004     Document Type: Article

References (29)

1. Benjamin EJ and Levy D. Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 317: 168-175, 1999.
2. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, and Clark WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 65: 657-670, 1989.
3. Burniston JG, Ng Y, Clark WA, Colyer J, Tan LB, and Goldspink DF. Myotoxic effects of clenbuterol in the rat heart and soleus muscle. J Appl Physiol 93: 1824-1832, 2002.
4. 2-Adrenergic receptor stimulation in vivo induces apoptosis in the rat heart and soleus muscle. J Appl Physiol 98: 1379-1386, 2005.
5. Cotter G, Kiowski W, Kaluski E, Kobrin I, Milovanov O, Marmor A, Jafari J, Reisin L, Krakover R, Vered Z, and Caspi A. Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure. Eur J Heart Fail 3: 457-461, 2001.
6. Doherty TJ. Aging and sarcopenia. J Appl Physiol 95: 1717-1727, 2003.
7. Duncan ND, Williams DA, and Lynch GS. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin Sci (Lond) 98: 339-347, 2000.
8. 2-adrenergic agonists on body composition and protein synthesis in the rat. Biosci Rep 4: 83-91, 1984.
9. Ferguson SSG. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53: 1-24, 2001.
10. Jeppsson AB, Waldeck B, and Widmark E. Further studies on the cardiomegaly induced by β-adrenoceptor agonists. Acta Pharmacol Toxicol 58: 121-125, 1986.
11. 2-adrenergic receptor mRNA by T-cell-restricted intracellular antigen-related protein. J Biol Chem 280: 1931-1943, 2005.
12. Kast A, Tsunenari Y, Honma M, and Iida H. Cardiac effects of fenoterol hydrobromide on newborn versus adult rats. Arzneimittelforschung 35: 188-192, 1985.
13. 17 phospholamban phosphorylation in the β-adrenergic regulation of cardiac relaxation. Am J Physiol Heart Circ Physiol 276: H1625-H1633, 1999.
14. Lakatta EG and Sollott SJ. Perspectives on mammalian cardiovascular aging: humans to molecules. Camp Biochem Physiol A Mol Integr Physiol 132: 699-721, 2002.
15. Larsson L and Ramamurthy B. Aging-related changes in skeletal muscle. Mechanisms and interventions. Drugs Aging 17: 303-316, 2000.
16. Leone M, Albanèse J, and Martin C. Positive inotropic stimulation. Curr Opin Crit Care 8: 395-403, 2002.
17. Lynch GS. Emerging drugs for sarcopenia: age-related muscle wasting. Expert Opin Emerging Drugs 9: 345-361, 2004.
18. Neely JR, Liebermeister H, Battersby EJ, and Morgan HE. Effect of pressure development on oxygen consumption by isolated rat heart. Am J Physiol 212: 804-814, 1967.
19. Roubenoff R. Sarcopenia: effects on body composition and function. J Gerontol A Biol Sci Med Sci 58: 1012-1017, 2003.
20. 2-Agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am J Physiol Kegul Integr Comp Physiol 283: R1386-R1394, 2002.
21. 2-Agonist administration reverses muscle wasting and improves muscle function in aged rats. J Physiol 555: 175-188, 2004.
22. Salpeter SR, Ormiston TM, and Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD. Chest 125: 2309-2321, 2004.
23. 2+ uptake in mammalian ventricular myocytes. Am J Physiol Heart Circ Physiol 261: H1344-H1349, 1991.
24. Sleeper MM, Kearns CF, and McKeever KH. Chronic clenbuterol administration negatively alters cardiac function. Med Sci Sports Exerc 34: 643-650, 2002.
25. Szymanska G, Strömer H, Silverman M, Belu-John Y, and Morgan JP. Altered phosphorylation of sarcoplasmic reticulum contributes to the diminished contractile response to isoproterenol in hypertrophied rat hearts. Pflügers Arch 439: 1-10, 1999.
26. Van Bilsen M, Snoeckx LHEH, Arts T, Van Der Vusse GJ, and Reneman RS. Performance of the isolated, ejecting heart: effects of aortic impedance and exogenous substrates. Pflügers Arch 419: 7-12, 1991.
27. Wong K, Boheler KR, Bishop J, Petrou M, and Yacoub MH. Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features. Cardiovasc Res 37: 115-122, 1998.
28. 2-adrenergic signal transduction. Circ Res 85: 1092-1110, 1999.
29. 2-adrenergic responses without changes in inhibitory G proteins or receptor kinases. J Clin Invest 101: 1273-1282, 1998.